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ABSTRACT 
Observational studies on long-term outcomes following debulking surgery or surgical biopsy for 
unresectable thymoma showed various results. This meta-analysis was designed to determine the 
effect of debulking surgery against surgical biopsy on overall survival in patients with unresectable 
thymoma. The PubMed database was queried for studies published in the English language on 
unresectable thymoma and overall survival. We compared overall survival following surgery in 
patients undergoing debulking surgery and patients undergoing surgical biopsy for unresectable 
thymoma. Meta-analysis was performed using the Mantel-Haenszel method, and potential 
publication bias was evaluated with a funnel plot of precision. No randomized trials on this topic 
were identified. Thirteen retrospective observational studies containing a sum of 314 patients with 
the number of deaths and person-year information were suitable for analysis. Information on 
Masaoka stages, World Health Organization histology, and indications for debulking surgery versus 
surgical biopsy was lacking in most studies. Diversity of neoadjuvant and adjuvant treatments was 
noted among the eligible studies. One hundred and seventy-two (54.8 %) underwent debulking 
surgery and 142 (45.2 %) underwent surgical biopsy. The pooled hazard ratio was 0.451 (95% 
confidence interval: 0.336-0.605, p<0.001), favouring patients undergoing debulking surgery 
compared with patients undergoing surgical biopsy. The funnel plot of precision demonstrated no 
important publication bias. Our results suggested that debulking surgery for unresectable thymoma 
may be associated with improved overall survival and be considered for patients with unresectable 
thymoma. 
 
Key words: thymoma, biopsy, surgery, survival 
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INTRODUCTION 
Although complete resection of thymoma has been reported as a significant favourable factor of 
improved overall survival [1-7], a portion of thymectomies for locally advanced thymoma end up 
with incomplete resection with or without neoadjuvant treatments [8-27]. From a surgical point of 
view, when faced with apparently unresectable thymoma or one which is deemed impossible to 
completely resect, for example, due to a number of desseminated nodules or great vessel 
involvement, in an operating room, thoracic surgeons are required to select from two options; 
debulking surgery versus surgical biopsy only. Some of previous observational studies suggested a 
significant difference in overall survival between patients undergoing debulking surgery and those 
undergoing surgical biopsy only [2,7,10,11,13, 14,16, 20, 22-24], while others did not 
[1,3-6,9,12,15,17,19]. There is a paucity of published data on the surgical management of 
unresectable thymoma. Given the absence of high quality evidence and the relatively small sizes of 
relevant published cohorts, we designed a quantitative meta-analysis to approach this question. 
 
MATERIALS & METHODS 
A search of the PubMed database (United States National Library of Medicine) using the terms 
thymoma, surgery, biopsy and survival resulted in 367 articles on 27th of September, 2013. The flow 
of selecting eligible articles was reported following the PRISMA statement (preferred reporting 
items for systematic reviews and meta-analysis, Figure 1). The abstracts of these 367 articles were 
independently reviewed by board-certified thoracic surgeons (M.H and F.K) and, as a result, 133 
abstracts, which included patients treated for locally advanced thymic epithelial tumors, were 
selected for review of full papers. Among the 133 studies, 25 studies which reported overall 
survival following surgery both for patients undergoing debulking surgery and patients undergoing 
surgical biopsy for locally advanced, unresectable thymoma were chosen for our review, after 
excluding the articles which analyzed both debulking surgery and surgical biopsy in the same group 
and the articles which analyzed only thymic carcinoma or thymic carcinoid. Then three articles 
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were excluded because overall survival was calculated from the date of adjuvant radiotherapy [1,12] 
and the date of diagnosis [20], not surgery. Among the 22 studies, which were reviewed by two 
study statisticians (Sato T and Sozu T), 13 studies from which infomation on the number of deaths 
and person-year information can be extracted were finally chosen for a quantitative meta-analysis 
[2-4,7-14,17,19, 24, 25]. The number of deaths and person-year were extracted from individual 
patient data in 4 studies and were approximately calculated from Kaplan-Meier plots in 7 studies, 
the number of deaths was reported and person-years were calculated from mean follow-up years in 
1 study, and the number of deaths in five years was reported and person-years were approximately 
calculated in 1 study (Table 1).  
In the analysis of studies with person-year information, we assumed exponential distribution as 
survival distributions in which the hazard within debulking surgery or surgical biopsy subgroup was 
constant by time. The combined estimate of the hazard ratio and its confidence interval were 
calculated by the Mantel-Haenszel method [28]. All confidence intervals are at the 95% level. 
Heterogeneity among studies was assessed by the I2 statistics. For the test of heterogeneity, we 
applied the same idea used in the Breslow-Day test of the odds ratio homogeneity to the Poisson 
conditional score test. We used JMP 10.0.2 (SAS Institute, Cary, NC) for statistical analysis. 
In addition, number of patients in each Masaoka stage and number of patients undergoing 
neoadjuvant or adjuvant chemotherapy and radiotherapy (or chemotherapy or radiotherapy 
following surgical biopsy or debulking surgery) in each patient group were extracted for reference 
but these data were not included in the meta-analysis. 
 
RESULTS 
Level of Available Evidence (‘‘Best Evidence’’) 
No randomized trials comparing debulking surgery and surgical biopsy for unresectable thymoma 
were found. We identified 13 retrospective cohort studies that described the number of deaths and 
person-year information following surgery both for patients undergoing debulking surgery and for 
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patients undergoing surgical biopsy (Table 1). Each of these 13 studies was a retrospective case 
series representing 8 to 74 patients with unresectable thymoma. A total of 314 patients comprised 
the study group; 172 (54.8%) underwent debulking surgery and 142 (45.2%) underwent surgical 
biopsy. 
 
Indications and descriptions for debulking surgery or surgical biopsy of unresectable 
thymoma. 
Selection criteria for patients undergoing debulking surgery or surgical biopsy for unresectable 
thymoma were not provided in any of the reviewed articles. The definition of debulking surgery 
was described in two articles as removing 90 % or more of tumor burden [13,14], while not 
described in the other articles. Debulking surgery was described as subtotal resection in 4 studies 
(30.8%) [2, 3, 24, 25], as partial resection in 6 studies (46.2%) [7, 9-11, 17, 19], as incomplete 
resection in one study (7.7%) [4], and as debulking surgery in 2 studies (15.4%) [13, 14].  
The approach for surgical debulking and surgical biopsy was specified (as sternotomy or 
thoracotomy, not mediastinoscopy, in all surgical biopsy patients) in 5 studies (38.5%) [9, 14, 19, 
24, 25], while not specified in the rest 8 studies. No minimally invasive approach was described in 
any article. 
    
Masaoka stage of unresectable thymomas 
Masaoka stages of unresectable thymoma in each category patients were available in 4 (30.8%) of 
the 13 studies (Table 2). Both in debulking surgery or surgical biopsy, there were no patients with 
Masaoka stage I or II thymoma, but only patients with stage III or stage IV thymoma. Most articles 
did not provide details on stage III (such as great vessel involvement) were not described, although 
Froudarakis et al [11] described all of stage III patients undergoing debulking surgery had great 
vessel involvement and Liu et al [14] described 7 (77.8%) of 9 stage III patients undergoing 
debulking surgery had great vessel involvement.  
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Neoadjuvant or adjuvant treatments (chemotherapy and radiotherapy) 
Data or description on the numbers of patients undergoing neoadjuvant chemotherapy and 
radiotherapy were available only in one study [4]. Data on the use of chemotherapy and/or 
radiotherapy following debulking surgery and surgical biopsy were available in 9 of the 13 studies 
(Table 3). Postoperative (adjuvant) radiotherapy was performed in 75-100 % (a median of 85.8%) 
of patients undergoing debulking surgery and 25-100 % (a median of 87.5%) of patients undergoing 
surgical biopsy, while (adjuvant) chemotherapy was performed in 14.3-42.9 % (a median of 27.5%) 
of patients undergoing debulking surgery and 25-75 % (a median of 47.8%) of patients undergoing 
surgical biopsy.  
 
Comparison of postoperative mortality and overall survival between patients undergoing 
debulking surgery and surgical biopsy for unresectable thymoma 
Postoperative mortality (within 30 days) was 0% for both debulking surgery and surgical biopsy in 5 
studies [4, 9, 10, 11, 19], and it was not available for each group in 6 studies [2, 7, 14, 17, 24, 25]. It was 
0% for debulking surgery but 14.3% for surgical biopsy in 1 study [3] and 0% for debulking surgery and 
9.1% for surgical biopsy in 1 study [13].  
Results of the quantitative meta-analysis for the 13 studies describing the number of deaths and 
person-year information following surgery (debulking surgery or surgical biopsy) were shown in 
Figure 2. As shown in Table 1, information on the number of deaths and person-years were 
extracted from 13 studies. Six of the 13 individual studies showed statistically significant hazard 
ratios favouring debulking surgery for unresectable thymoma compared with surgical biopsy. The 
pooled hazard ratio using the Mantel-Haenszel method was 0.451 (95% confidence interval: 
0.336-0.605, P < 0.001). 
   Five-year overall survival rate by Kaplan-Meier method ranged from 16% to 100%, with a 
median of 64% in patients undergoing debulking surgery, while the rate ranged from 0% to 66.7%, 
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with a median of 35% in patients undergoing surgical biopsy. 
    
Publication bias and/or heterogeneity of results reported in each individual study  
Figure 3 shows a funnel plot of precision by log hazard ratio for the 13 studies describing the 
number of deaths and person-year information following surgery (debulking surgery or surgical 
biopsy). The plot showed that all the studies fall within the funnel and most are centered on the 
median axis, suggesting a lack of important publication bias. I2=58% showed a moderate 
heterogeneity among 13 included studies.  
 
DISCUSSION 
Given the overall incidence of thymoma and its relatively indolent biologic behaviour, the current dearth 
of data on the management of unresectable thymoma is not surprising. These same factors essentially 
preclude organization of a randomized controlled trial on the treatment of unresectable thymoma patients. 
Our current knowledge of this problem is derived exclusively from level 3 evidence in the form of 
retrospective case series, and there have been no prospective studies focusing on this patient population. 
We therefore designed a quantitative meta-analysis to explore the utility of debulking surgery against 
surgical biopsy in this group of patients. 
Our meta-analysis was constructed from 13 studies published from 1981 to 2006 and represented 
314 patients treated for unresectable thymoma in the United States, Japan, China, Spain, Greece, Taiwan, 
and Italy [2-4, 7-14, 17, 19, 24, 25]. The results of our quantitative meta-analysis demonstrated that 
patients undergoing debulking surgery for unresectable thymoma had improved overall survival 
compared to patients undergoing surgical biopsy. All surgical biopsies were performed via sternotomy or 
thoracotomy in the 5 studies describing the approach in this meta-analysis. With respect to high 
diagnostic yield (80-100%) of recent image guided percutaneous techniques of mediastinal mass [29, 30], 
it may be reasonable to consider more than diagnostic procedures once sternotomy or thoracotomy is 
performed.  
The role of multimodality therapy in the management of unresectable thymoma could not be 
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fully evaluated in this study because the only description on neoadjuvant treatments for both groups 
was available in the article of Rea et al [4] and no neoadjuvant treatments apparently were 
performed in the other 12 studies. Neoadjuvant chemotherapy or chemoradiotherapy followed by 
surgery may be promising treatment modalities for locally advanced unresectable thymoma, but the 
long-term outcomes are pending [31,32]. 
It should be noted that patients in the included studies underwent debulking surgery versus 
surgical biopsy, followed by (adjuvant) radiotherapy and/or by chemotherapy. Although statistical 
analysis was not performed, radiotherapy appeared to be performed frequently following both 
debulking surgery and surgical biopsy and to be performed more frequently than chemotherapy. 
Adjuvant chemotherapy apparently was performed more frequently in patients undergoing surgical 
biopsy than those undergoing debulking surgery in our study. As pointed out in several studies [3, 
13, 14], adjuvant radiotherapy may improve overall survival following debulking surgery or 
surgical biopsy for locally advanced unresectable thymoma. Adjuvant chemotherapy has been less 
discussed and performed than radiotherapy as an adjuvant treatment, but may be considered 
following debulking surgery [26]. Given that except for the 13 included studies, there have been 
only a few articles on patients undergoing radiotherapy only, chemotherapy only or 
chemoradiotherapy only [33-35], this meta-analysis is noted for investigating debulking surgery 
versus biopsy only prior to chemotherapy, radiotherapy, or chemoradiotherapy. The superiority of 
debulking surgery over surgical biopsy in this meta-analysis should be understood in the setting of 
frequent postoperative treatments.  
Meta-analyses are useful tools for the evaluation of rare populations such as ours, but they are 
inherently constrained by the limitations of the original studies from which they are comprised. In 
addition, a meta-analysis of retrospective cohort studies included another limitation: hazard ratio of 
a treatment to the other in overall survival is rarely described or available. Several studies other than 
13 eligible studies were excluded because they reported only 5 year or 10 year overall survival rates 
and did not help estimate hazard ratio in overall survival, while Kaplan-Meier curves in 7 studies in 
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our meta-analysis were helpful in estimating the number of death and person-year information. 
Although I2 of 58% in our meta-analysis suggested a moderate heterogeneity, but debulking surgery 
is still considered favorable because only 3 studies [9, 11, 19] showed more than 1 of hazard ratio 
(debulking surgery unfavorable) in the forest plot. Our funnel plot analyses did not demonstrate an 
important relationship between treatment effect and study size, and therefore suggested the absence 
of important publication bias.  
Our meta-analysis demonstrates improved overall survival in patients operated on with radical 
intents undergoing debulking surgery for unresectable thymoma, compared to those undergoing 
surgical biopsy. Although selection biases were present in each of the original studies in our 
meta-analysis, the improved overall survival in the debulking group suggests a consideration of 
aggressive debulking in patients with unresectable thymoma unless preoperative workup shows too 
extensive diseases such as multiple vascular involvement or numerous pleural implants.  
Since neoadjuvant treatments could not be evaluated in this meta-analysis, a potential future 
analysis will be to investigate the effect of debulking surgery following neoadjuvant chemotherapy 
or chemoradiotherapy on long-term outcomes in locally advanced (presumably unresectable at 
presentation) thymomas.  
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TABLES 










5y OS *Information extracted 
Chahinian et al [9] 1981 8 4 50% 4 0% a 
Masaoka et al [3] 1981 20 13 69.2% 7 57.1% a 
Cohen et al [19] 1984 10 7 14.3% 3 66.7% b 
Maggi et al [24] 1991 30 21 71.7% 9 40% c 
Wang L [17] 1992 27 9 40% 18 45% c 
Egea et al [10] 1995 11 7 15% 4 0% c 
Froudarakis et al 
[11] 
2001 15 3 100% 12 8.3% 
a 
Rios et al [7] 2002 14 10 50% 4 0% c 
Kondo et al [2] 2003 74 50 64.4% 24 35.6% c 
Wang Y et al [25] 2003 20 14 66.4% 6 16.7% d 
Lin et al [13] 2004 18 7 85% 11 45% a 
Rea et al [4] 2004 24 12 16% 12 33% c 
Liu et al [14] 2006 43 15 71% 28 35% c 
OS; overall survival, ND; no data, RT; radiotherapy, KM; Kaplan-Meier 
*Information extracted 
a. Number of deaths and person-years were calculated from individual data. 
b. Number of deaths was reported and person-years were calculated from mean follow-up years. 
c. Number of deaths and person-years were approximately calculated from Kaplan-Meier plots. 
d. Number of deaths in five years was reported and person-years were approximately calculated. 
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Table 2. Masaoka stages at surgery in patients undergoing debulking surgery and those undergoing 






stage III stage IV 
biopsy 
(N) 
stage III stage IV 










A; 2 (28.6%)     
B; 1 (14.3%) 
Froudarakis et al 
[11] 
2001 15 3 3 (20%) 0 12 3 (25%) 9 (75%) 








A; 4 (36.4%) 





ND; no data         
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Table 3. Number of patients undergoing chemotherapy and/or radiotherapy following debulking 
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%) %) 





12 ND ND 12 ND ND 





15 ND ND 28 ND ND 
Chemo; chemotherapy, RT; radiotherapy, ND; no data 
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Figure legends 
Figure 1. The flow of selecting eligible papers following PRISMA (preferred reporting items for 
systematic reviews and meta-analysis) statement. 
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Figure 2. Comparisons of overall survival following surgery in patients treated with debulking 
surgery and surgical biopsy, with meta-analysis using Mantel-Haenszel method. The left portions of 
the figure show the studies analyzed with their corresponding hazard ratio, lower and upper limits, 
and P value. The right portions of the figure show a forest plot of the data. The horizontal lines 
represent the values within the 95% confidence interval (CI) of the underlying effects. The vertical 
line indicates a hazard ratio of 1. 
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Figure 3. A funnel plot of precision by log hazard ratio showed that all the studies fall almost 
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0.0-1.0-2.0-3.0-4.0-5.0 1.0 2.0 3.0
log hazard ratio
Debulking Biopsy
Study Deaths Person-years Deaths Person-years Hazard ratio
Chahinian et al [9] 3 17.4 2 16.5 1.42
Masaoka et al [3] 4 62.25 4 9.59 0.154
Cohen et al [19] 5 15.0 3 18.0 2.00
Maggi et al [24] 6 120.0 6 27.5 0.229
Wang et al [17] 6 36.33 14 81.67 0.963
Egea et al [10] 7 19.5 4 4.0 0.359
Froudarakis et al [11] 1 18.0 11 13.42 0.068
Rios et al [7] 8 52.0 4 4.75 0.183
Wang et al [2] 5 57.5 5 17.5 0.304
Kondo et al [25] 20 232.5 15 67.5 0.387
Lin et al [13] 2 57.79 8 44.58 0.193
Rea et al [4] 11 39.25 10 45.24 1.27
Liu et al [14] 3 58.0 14 83.0 0.307
Total 81 785.52 100 433.25 0.451
Figure 2
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